Medicare News In Brief
This article was originally published in The Gray Sheet
Executive Summary
New-tech intraocular lens: CMS is considering whether Rayner Surgical's C-flex Model 570C intraocular lens meets the criteria for a new class of new-technology IOLs. The designation would provide a $50 payment bonus for lenses implanted for cataracts in ambulatory surgical centers for five years. Rayner Surgical says its product, which was approved by FDA in May 2007, reduces silicone oil adhesion and oil-induced opacification associated with vitreoretinal surgery. CMS questions whether the benefit is clinically demonstrable compared with other IOLs. Under current new-tech IOL classifications, four lenses are eligible for a bonus payment through February 2011 based on their ability to reduce spherical aberrations: Advanced Medical Optics' Tecnis, Alcon's Acrysof IQ, Bausch & Lomb's Sofport AO and STAAR's Affinity Collamer (1"The Gray Sheet" March 19, 2007, In Brief)
You may also be interested in...
Ambulatory Surgical Center Payment Reform Enacted; Facilities Bitter
CMS finalized July 16 a restructured payment system for ambulatory surgical centers that the facilities claim will reduce payments for many procedures. The policy is an attempt by CMS to prevent reimbursement considerations from outweighing clinical considerations in determining where medical procedures are performed
B&L lens payment bonus
Bausch & Lomb's SofPort AO and SofPort AO with Violet Shield intraocular lenses receive new technology IOL designations from CMS, effective March 6. Joining lenses from AMO (Tecnis and Tecnis CL) and Alcon (AcrySof IQ), Bausch & Lomb's IOLs will now also receive a $50 Medicare bonus payment when used in cataract procedures performed in ambulatory surgical centers through Feb. 27, 2011. The three firms' lenses reduce spherical aberrations for better vision quality relative to standard IOLs (1"The Gray Sheet" May 29, 2006, In Brief)...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.